It is also unclear whether any negative health effects may emerge with prolonged use, how pillbased options might influence adherence, and how regulators, insurers and health systems will adapt as usage grows
Markets that treat affordability thresholds as strategic levers, not afterthoughts, will own the volume growth phase of global GLP-1 adoption
Comparison between GLP-1 RA and the GLP-1/GIP dual agonist (tirzepatide) Tirzepatide vs GLP-1 Struggling to lose weight even when you are eating less can feel frustrating
Impact on AMD A 2025 retrospective published in JAMA Ophthalmology looked at the incidence of developing wet age-related macular degeneration (AMD) three years after initiation of treatment with GLP-1 drugs
It belongs to a broader category of GLP-1 receptor agonists, and understanding how it compares to alternatives helps researchers make informed decisions about which compound best serves their specific research objectives
Additional Phase 3 trials are still underway, including TRIUMPH-2 (evaluating retatrutide in adults with obesity and type 2 diabetes) and TRIUMPH-3 (evaluating cardiovascular outcomes), with results expected later in 2026
